Stay updated on Nivolumab vs Docetaxel in NSCLC: Clinical Trial
Sign up to get notified when there's something new on the Nivolumab vs Docetaxel in NSCLC: Clinical Trial page.

Latest updates to the Nivolumab vs Docetaxel in NSCLC: Clinical Trial page
- Check6 days agoNo Change Detected
- Check14 days agoChange DetectedThe changes are minor version-tag updates: Revision: v3.4.2 added and Revision: v3.4.1 removed; no impact on study content or how users interact with the page. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.3%

- Check21 days agoChange DetectedAdded a site-wide funding-status notice indicating possible data delays and directing users to cc.nih.gov and opm.gov, and updated the page revision from v3.4.0 to v3.4.1. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.3%

- Check28 days agoChange DetectedShow glossary and updated metadata (Last Update Submitted that Met QC Criteria, No FEAR Act Data, Revision: v3.4.0) were added and older metadata (Last Update Submitted that met QC Criteria, No FEAR Act data, Revision: v3.3.4) were removed.SummaryDifference0.2%

- Check42 days agoChange DetectedRevision updated from v3.3.3 to v3.3.4 on the page; this is a minor metadata update with no changes to study content, eligibility, or results. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check63 days agoChange DetectedThe study location sections were consolidated under a single 'Locations' heading and list the regions (Beijing Municipality, Chongqing Municipality, Fujian, Guangdong, Henan, Hunan, Jiangsu, Jilin, Shanghai Municipality, Sichuan, Zhejiang). The previous per-location 'X Locations' subsections were removed and a revision note (Revision: v3.3.3) was added.SummaryDifference1%

- Check92 days agoChange DetectedAdded a PubMed auto-fill note clarifying that publications may not all relate to the study. Updated the revision label to v3.3.2 (replacing the prior v3.2.0 wording).SummaryDifference0.1%

Stay in the know with updates to Nivolumab vs Docetaxel in NSCLC: Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Nivolumab vs Docetaxel in NSCLC: Clinical Trial page.